Considering the promising cardiorenal outcomes of GLP-1 RA in patients with T2DM and cardiovascular diseases, a great cardioprotective potential could be assessed in cancer patients treated with cardiotoxic therapies. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.